X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
RAD204, which targets PDL1-positive NSCLC, which used technology underpinning the trial is Radiopharm’s proprietary nanobody from its NanoMab platform.
Lead Product(s): RAD204
Therapeutic Area: Oncology Product Name: RAD204
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 09, 2023
Details:
Under the agreement, TerThera will supply Radiopharm with Terbium-161 and Tb-161 isotope will be linked to a proprietary mAb to form RAD 402, a radiotherapeutic that is being developed by Radiopharm to target KLK3 expression in patients with advanced prostate cancer.
Lead Product(s): RAD 402,Terbium-161
Therapeutic Area: Oncology Product Name: RAD 402
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: TerThera
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 24, 2023
Details:
RAD301 (68Ga-Trivehexin) is a proprietary peptide-based molecule that targets avf6-integrin, a cellular marker for tumor invasion and metastatic growth, the expression of which correlates with decreased survival in several carcinomas.
Lead Product(s): 68Ga-Trivehexin
Therapeutic Area: Oncology Product Name: RAD301
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 09, 2023
Details:
The agreement aims to supply Tb-161 for RAD 602, a radiotherapeutic that is being developed by Radiopharm to target protein tyrosine phosphatase mu (PTPmu or PTPμ) for treatment of brain cancers.
Lead Product(s): RAD602
Therapeutic Area: Oncology Product Name: RAD602
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: TerThera
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 17, 2023
Details:
Pharma15 is developing assets which seek to overcome resistance to prostate-specific membrane antigen (PSMA) targeting cancer therapies currently available or in late-stage development.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Pharma15
Deal Size: $4.0 million Upfront Cash: $2.0 million
Deal Type: Acquisition March 03, 2023
Details:
The isotope will be used by Radiopharm in the development of its clinical pipeline of diagnostic and therapeutic radiopharmaceutical products including RAD206. Lu-177 is an important isotope utilized in multiple programs across Radiopharm’s portfolio.
Lead Product(s): n.c.a Lutetium-177
Therapeutic Area: Oncology Product Name: RAD206
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: SHINE Technologies
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 19, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
